BERKELEY HEIGHTS, NJ - November 1, 2005-
Genta Incorporated (Nasdaq: GNTA), announced that Genasense®
(oblimersen sodium) Injection, the Company's lead anticancer
compound, will be featured in presentations at the twenty-third
annual symposium of the Chemotherapy Foundation in New York, NY.
Investigators will review and discuss the activity and safety of
Genasense in combination with chemotherapy from the Company's
pivotal clinical studies in malignant melanoma and chronic
lymphocytic leukemia. Highlighted presentations include the
following:
- Wednesday, November 2, 2005; 9:35 AM Bcl-2 Antisense Therapy
in Chronic Lymphocytic Leukemia. Kanti R. Rai, M.D., Chief,
Hematology and Oncology, North Shore/Long Island Jewish Medical
Center, and Professor of Medicine, Albert Einstein College of
Medicine.
- Friday, November 4, 2005; 2:35 P.M. Bcl-2 Antisense Therapy
in Melanoma Frank G. Haluska, M.D., Ph.D, Director,
Dana-Farber/Partners CancerCare Melanoma Program, and Assistant
Professor of Medicine, Harvard Medical School.
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer
cells that is thought to block chemotherapy-induced apoptosis
(programmed cell death). By reducing the amount of Bcl-2 in cancer
cells, Genasense may enhance the effectiveness of current
anticancer treatment. Genta is pursuing a broad clinical
development program with Genasense to evaluate its potential to
treat various forms of cancer. In addition, Genta has established a
Cooperative Research and Development Agreement (CRADA) with the
U.S. National Cancer Institute (NCI), which has initiated
additional clinical trials. Information about the NCI-sponsored
studies can be obtained at:
http://www.clinicaltrials.gov/ct/search;jsessionid=50D3886BAAE768BEA0DE36526F68%20083B?term=oblimersen
About Genta
http://www.genta.com/
This press release contains forward-looking statements with
respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks
and uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual Report/Form 10-K
for 2004.
